Home > 2020 > September 2020
September 2020
This was a loaded month for pioneering drug discovery programs! Among the highlights are a reversible-covalent inhibitor from Novartis, the hotly followed SHP2 inhibitor from Novartis, several innovative compounds from Pfizer including an oral GLP-1R agonist with a cryo-EM structure, a liver-targeted ACC inhibitor, and an oral KHK inhibitor. Remarkably, half of the molecules are negatively charged or pro-drugs of anions, and several have oral bioavailability beyond what a chemist 20 years ago would have thought probable. Most of these don’t look like they would be low-clearance, high bioavailability drugs, but they are! Detailed comments and links below.
Join the Drug Hunter mailing list, trusted by >4,000 drug hunters worldwide. Drug Hunter content only, unsubscribe anytime.
nominate a molecule
Encountered an interesting new molecule? Let your community know!
become a reviewer
Get sneak previews of upcoming molecules and share your knowledge and expertise with the drug discovery community.
past molecules of the month
Check out previous selections below.
molecules of the year nominees
Previous selections for Drug Hunter’s Molecule of the Year below.
hall of fame
molecules of the year
Previous selections for Drug Hunter’s Molecule of the Year below.
Work smarter in two minutes. Join >4,000 drug hunters from every major biopharma company in the world getting drug discovery updates through our Drug Hunter e-mail newsletter. Unsubscribe anytime.
JOIN SUBSCRIBERS from
- Johnson & Johnson
- Roche
- Pfizer
- Novartis
- Bayer
- Merck
- Sanofi
- GlaxoSmithKline
- AbbVie
- Eli Lilly
- Boehringer Ingelheim
- Amgen
- Bristol-Myers Squibb
- Gilead
- AstraZeneca
- Teva
- Novo Nordisk
- Merck KGaA
- Takeda
- Celgene (BMS)
- Biogen
- Astellas
- Daiichi Sankyo
- Regeneron
- UCB
- Eisai
- Servier
- Kyowa Kirin
- Shionogi
- Vertex
- Lundbeck
- Taisho
- Ono
- Seagen
- Incyte
- LEO Pharma
- Janssen
- Galapagos
- Idorsia
- Astex
- Arvinas
- Kymera
- Relay
- Schrodinger
- Mirati
- Revolution
- Nimbus
- Plexxikon
- Forma
- Arcus
- RA Capital
- ARCH Venture Partners
- MPM Capital
- Orbimed
- The Column Group
- 5AM Ventures
- Versant Ventures
- Deerfield
- Goldman Sachs
- Citi
- Piper Sandler
- Softbank
- …and hundreds of others